Definitely a binary situation. I'm confident that the DME study will go well. Other VEGF-A drugs work here and are Standard of Care.
Too bad the market are panicky, the valuation / potential buyout would be at higher prices, if that occurs.
If DME successful, Big Pharma will be very interested in a combo treatment.
Sometimes the hardest trade is the one in high anxiety markets, but it creates opportunity. GLTA.
Ann: Opthea Completes Patient Dosing in Phase 2a DME Trial, page-6
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
86.8¢ |
Change
-0.028(3.07%) |
Mkt cap ! $1.064B | |||
| Open | High | Low | Value | Volume |
| 88.5¢ | 88.5¢ | 85.8¢ | $2.022M | 2.333M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 22937 | 86.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 87.0¢ | 17400 | 15 |
View Market Depth
| Last trade - 14.05pm 08/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |